MA49133A - Anticorps agonistes anti-btla et leurs utilisations - Google Patents

Anticorps agonistes anti-btla et leurs utilisations

Info

Publication number: MA49133A
Authority: MA; Morocco
Prior art keywords: agonist antibodies; btla agonist; btla; antibodies; agonist
Prior art date: 2017-05-19

Application number

MA049133A

Other languages

English (en)

Inventor

Shane Krummen Atwell

Victor H Obungu

Andrew Charles Vendel

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-19

Filing date

2018-05-11

Publication date

2020-03-25

2018-05-11 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2020-03-25 Publication of MA49133A publication Critical patent/MA49133A/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA049133A 2017-05-19 2018-05-11 Anticorps agonistes anti-btla et leurs utilisations MA49133A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762508510P	2017-05-19	2017-05-19

Publications (1)

Publication Number	Publication Date
MA49133A true MA49133A (fr)	2020-03-25

Family

ID=62245543

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA049133A MA49133A (fr)	2017-05-19	2018-05-11	Anticorps agonistes anti-btla et leurs utilisations

Country Status (26)

Country	Link
US (2)	US10604573B2 (fr)
EP (1)	EP3625257A1 (fr)
JP (2)	JP6790304B2 (fr)
KR (3)	KR102294051B1 (fr)
CN (3)	CN110621699B (fr)
AR (1)	AR111752A1 (fr)
AU (2)	AU2018269585B2 (fr)
BR (1)	BR112019021547A2 (fr)
CA (2)	CA3064518A1 (fr)
CL (1)	CL2019003215A1 (fr)
CO (1)	CO2019012756A2 (fr)
CR (1)	CR20190521A (fr)
DO (1)	DOP2019000293A (fr)
EA (1)	EA201992460A1 (fr)
EC (1)	ECSP19082184A (fr)
JO (1)	JOP20190261A1 (fr)
MA (1)	MA49133A (fr)
MX (1)	MX381033B (fr)
MY (2)	MY197425A (fr)
NZ (1)	NZ758360A (fr)
PE (1)	PE20191843A1 (fr)
PH (1)	PH12019502575A1 (fr)
SA (1)	SA519410534B1 (fr)
TW (4)	TWI747043B (fr)
WO (1)	WO2018213113A1 (fr)
ZA (1)	ZA201906954B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201820554D0 (en)	2018-12-17	2019-01-30	Univ Oxford Innovation Ltd	BTLA antibodies
EP4045641A1 (fr)	2019-10-15	2022-08-24	Eli Lilly and Company	Lignées cellulaires mammifères déficientes en lipase/estérase modifiées par recombinaison
GB202008860D0 (en)	2020-06-11	2020-07-29	Univ Oxford Innovation Ltd	BTLA antibodies
MX2023004633A (es) *	2020-10-23	2023-05-12	Anaptysbio Inc	Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
EP4469558A4 (fr) *	2022-01-29	2026-02-25	Hifibio Inc	Anticorps anti-btla et leurs utilisations dans le traitement du cancer
AU2023212896A1 (en) *	2022-01-29	2024-08-22	Hifibio, Inc.	Antibody against btla and uses thereof
WO2024040195A1 (fr)	2022-08-17	2024-02-22	Capstan Therapeutics, Inc.	Conditionnement pour l'ingénierie de cellules immunitaires in vivo
EP4626929A2 (fr) *	2022-12-02	2025-10-08	Eli Lilly and Company	Anticorps agonistes de btla et leurs utilisations
WO2024243594A1 (fr) *	2023-05-25	2024-11-28	Anaptysbio, Inc.	Agoniste de btla pour la modulation de cellules dendritiques
WO2026053130A1 (fr) *	2024-09-03	2026-03-12	Mirobio Limited	Anticorps anti-btla et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8546541B2 (en)	2002-06-20	2013-10-01	Washington University	Compositions and methods for modulating lymphocyte activity
US7153950B2 (en) *	2002-10-25	2006-12-26	Genentech, Inc.	Nucleic acids encoding an immune related polypeptide
MX2009005189A (es) *	2006-11-15	2009-06-30	Medarex Inc	Anticuerpos humanos monoclonales para btla y metodos de uso.
CA2769473A1 (fr) *	2009-07-31	2011-02-03	N.V. Organon	Anticorps totalement humains diriges contre le btla
US9533039B2 (en) *	2010-09-27	2017-01-03	Regeneron Pharmaceuticals, Inc.	Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (fr) *	2012-07-26	2014-01-30	The General Hospital Corporation	Méthodes et compositions pour le traitement d'une maladie auto-immune
WO2014183885A1 (fr) *	2013-05-17	2014-11-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antagoniste de l'interaction btla/hvem pour une utilisation en thérapie
EP3288587A4 (fr) *	2015-04-29	2018-09-12	Sanford-Burnham Medical Research Institute	Modulation de réponse immunitaire au moyen d'anticorps agonistes de btla
JP7227007B2 (ja) *	2015-12-02	2023-02-21	ストサイエンシス，インコーポレイテッド	グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体

2017
- 2017-06-16 JO JOP/2019/0261A patent/JOP20190261A1/ar unknown
2018
- 2018-05-03 AR ARP180101158A patent/AR111752A1/es not_active Application Discontinuation
- 2018-05-04 TW TW108133289A patent/TWI747043B/zh not_active IP Right Cessation
- 2018-05-04 TW TW107115166A patent/TWI677504B/zh not_active IP Right Cessation
- 2018-05-04 TW TW112116965A patent/TW202334237A/zh unknown
- 2018-05-04 TW TW110141711A patent/TWI804044B/zh not_active IP Right Cessation
- 2018-05-11 JP JP2020511876A patent/JP6790304B2/ja active Active
- 2018-05-11 EA EA201992460A patent/EA201992460A1/ru unknown
- 2018-05-11 MY MYPI2019006702A patent/MY197425A/en unknown
- 2018-05-11 CN CN201880033180.XA patent/CN110621699B/zh active Active
- 2018-05-11 CN CN202311364322.XA patent/CN117402245A/zh active Pending
- 2018-05-11 US US15/977,003 patent/US10604573B2/en active Active
- 2018-05-11 EP EP18727622.5A patent/EP3625257A1/fr active Pending
- 2018-05-11 PE PE2019002417A patent/PE20191843A1/es unknown
- 2018-05-11 CR CR20190521A patent/CR20190521A/es unknown
- 2018-05-11 CA CA3064518A patent/CA3064518A1/fr active Pending
- 2018-05-11 MY MYPI2021007625A patent/MY198277A/en unknown
- 2018-05-11 BR BR112019021547-6A patent/BR112019021547A2/pt active Search and Examination
- 2018-05-11 CA CA3184628A patent/CA3184628A1/fr active Pending
- 2018-05-11 KR KR1020197033639A patent/KR102294051B1/ko active Active
- 2018-05-11 NZ NZ758360A patent/NZ758360A/en not_active IP Right Cessation
- 2018-05-11 KR KR1020217026470A patent/KR20210106033A/ko not_active Ceased
- 2018-05-11 WO PCT/US2018/032218 patent/WO2018213113A1/fr not_active Ceased
- 2018-05-11 MX MX2019013604A patent/MX381033B/es unknown
- 2018-05-11 MA MA049133A patent/MA49133A/fr unknown
- 2018-05-11 KR KR1020227039792A patent/KR20220158847A/ko not_active Ceased
- 2018-05-11 AU AU2018269585A patent/AU2018269585B2/en active Active
- 2018-05-11 CN CN202311364321.5A patent/CN117402244A/zh active Pending
2019
- 2019-10-22 ZA ZA2019/06954A patent/ZA201906954B/en unknown
- 2019-11-08 CL CL2019003215A patent/CL2019003215A1/es unknown
- 2019-11-12 SA SA519410534A patent/SA519410534B1/ar unknown
- 2019-11-15 CO CONC2019/0012756A patent/CO2019012756A2/es unknown
- 2019-11-15 DO DO2019000293A patent/DOP2019000293A/es unknown
- 2019-11-18 PH PH12019502575A patent/PH12019502575A1/en unknown
- 2019-11-18 EC ECSENADI201982184A patent/ECSP19082184A/es unknown
2020
- 2020-02-17 US US16/792,396 patent/US11396545B2/en active Active
- 2020-11-04 JP JP2020184527A patent/JP7072622B2/ja active Active
2021
- 2021-12-02 AU AU2021277743A patent/AU2021277743A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2018213113A1 (fr)	2018-11-22
JP2021019642A (ja)	2021-02-18
AU2018269585A1 (en)	2019-10-31
EP3625257A1 (fr)	2020-03-25
SA519410534B1 (ar)	2023-11-08
US10604573B2 (en)	2020-03-31
MX381033B (es)	2025-03-12
MY198277A (en)	2023-08-18
CN110621699A (zh)	2019-12-27
ZA201906954B (en)	2021-06-30
PE20191843A1 (es)	2019-12-31
AU2021277743A1 (en)	2021-12-23
TW201904991A (zh)	2019-02-01
TW202233681A (zh)	2022-09-01
JP7072622B2 (ja)	2022-05-20
DOP2019000293A (es)	2019-12-15
PH12019502575A1 (en)	2020-07-13
TW201946932A (zh)	2019-12-16
NZ758360A (en)	2022-10-28
US11396545B2 (en)	2022-07-26
CA3064518A1 (fr)	2018-11-22
JP2020518288A (ja)	2020-06-25
CN117402245A (zh)	2024-01-16
CA3184628A1 (fr)	2018-11-22
TWI677504B (zh)	2019-11-21
AU2018269585B2 (en)	2021-09-02
US20200239578A1 (en)	2020-07-30
KR102294051B1 (ko)	2021-08-27
EA201992460A1 (ru)	2020-03-18
US20180334502A1 (en)	2018-11-22
CN110621699B (zh)	2023-10-31
CL2019003215A1 (es)	2020-04-13
CO2019012756A2 (es)	2020-01-17
TWI804044B (zh)	2023-06-01
ECSP19082184A (es)	2019-11-30
JP6790304B2 (ja)	2020-11-25
MY197425A (en)	2023-06-16
CN117402244A (zh)	2024-01-16
TWI747043B (zh)	2021-11-21
AR111752A1 (es)	2019-08-14
CR20190521A (es)	2020-01-06
TW202334237A (zh)	2023-09-01
KR20210106033A (ko)	2021-08-27
KR20220158847A (ko)	2022-12-01
KR20190140969A (ko)	2019-12-20
MX2019013604A (es)	2019-12-18
BR112019021547A2 (pt)	2020-05-12
JOP20190261A1 (ar)	2019-11-05

Publication	Publication Date	Title
EP3625263A4 (fr)	2021-05-05	Anticorps anti-galectine-9 et leurs utilisations
EP3891183A4 (fr)	2022-08-31	Anticorps anti-claudine et leurs utilisations
EP3383916A4 (fr)	2019-09-11	Anticorps anti-cd73 et leurs utilisations
EP3759143A4 (fr)	2022-03-02	Anticorps anti-tigit et leurs utilisations
EP3389702A4 (fr)	2019-08-14	Anticorps anti-lag-3 et leurs utilisations
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
EP3762030A4 (fr)	2022-01-05	Anticorps anti-cd73 et utilisations associées
EP3504243A4 (fr)	2020-03-11	Anticorps anti-tim-3 et leurs utilisations
MA49687A (fr)	2020-06-03	Anticorps anti-ctla-4 et leurs utilisations
EP3426288A4 (fr)	2019-10-30	Anticorps anti-pacap et leurs utilisations
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
EP3684812A4 (fr)	2021-09-08	Anticorps anti-ctla4 et utilisations associées
EP3328895A4 (fr)	2019-08-21	Anticorps anti-pd-l1 et leurs utilisations
EP3400243A4 (fr)	2019-09-25	Anticorps anti-pd-l1 et utilisations associées
EP3735427A4 (fr)	2021-09-15	Anticorps anti-mct1 et utilisations associées
EP3283517A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
EP3733702A4 (fr)	2021-09-29	Anticorps anti-lag-3 et utilisations associées
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
EP3645563A4 (fr)	2021-03-17	Anticorps anti-fam19a5 et leurs utilisations
EP3790586A4 (fr)	2022-01-19	Anticorps anti-dll3 et leurs utilisations
MA45233A (fr)	2019-04-17	Anticorps anti-gitr et leurs utilisations
EP3661555A4 (fr)	2021-07-14	Anticorps bispécifiques et leurs utilisations
EP3672987A4 (fr)	2021-08-18	Anticorps anti-apéline et leurs utilisations